Search results
Results from the WOW.Com Content Network
In 2005, the FDA held a Congressional hearing to review the situation. [21] The U.S. is an especially attractive market for counterfeiters, because 40% of worldwide annual prescription drug sales were made in the United States in 2007. [24] In 2011, a "PROTECT IP Act" was proposed to deter advertising.
GoodRx was founded in Santa Monica, California, in 2011. In 2017, the company announced partnerships with major pharmaceutical companies to negotiate lower prescription drug costs. [6] [8] In September 2019, GoodRx acquired the telemedicine company HeyDoctor and rebranded the telemedicine platform as GoodRx Care. [3]
Phentermine is an norepinephrine and dopamine releasing agent (NDRA) and produces stimulant, rewarding, and appetite suppressant effects. [8] [9] [10] Chemically, it is a substituted amphetamine. [11] Phentermine was approved for medical use in the United States in 1959. [3] It is available as a generic medication. [3]
Present the GoodRx Gold card at the pharmacy counter or show the app to access savings. Cost: Individual plans are available for $9.99 per month and family plans are available for up to six people ...
Last year, California signed a 10-year agreement with the nonprofit Civica to produce CalRx branded insulin, which is used to treat diabetes. California has set aside $100 million for that project, with $50 million to develop the drugs and the rest set aside to invest in a manufacturing facility. Newsom said a 10 milliliter vial of state ...
Voting yes on Prop. 34 is a vote in favor of stricter rules governing certain California nonprofits that participate in the federal 340B program, requiring them to spend at least 98% of their ...
To avoid this scam, credit card holders should know that legitimate companies do not usually urge customers to provide sensitive personal information over the phone or via an unsecured online ...
Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.